| Laurelwood Healthcare Center | |
| 200 Birch St, Jackson, Tennessee 38301 | |
| (731) 422-5641 | |
| Name | Laurelwood Healthcare Center |
|---|---|
| Location | 200 Birch St, Jackson, Tennessee |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 64 |
| Occupancy Rate | 84.38% |
| Medicare ID (CCN) | 445413 |
| Legal Business Name | Lhc, Inc. |
| Ownership Type | For Profit - Partnership |
| NPI Number | 1922177120 |
| Organization Name | LHC, INC. |
| Doing Business As | LAURELWOOD HEALTH CARE |
| Address | 200 Birch St, Jackson, TN 38301 |
| Phone Number | 731-422-5641 |
News Archive
Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).
More than 100 million people in this country have pain that won't go away. Many of these chronic pain sufferers fail to get relief from pills, shots and even surgery, while others temporarily trade the pain for side effects such as drowsiness or digestive problems.
Generex Biotechnology Corporation announced today that the Company's wholly-owned subsidiary Antigen Express, Inc. presented an update of the ongoing Phase 2 trial with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in patients with breast cancer at Cambridge Healthtech Institute's Sixth Annual ImVacS: The Immunotherapeutics and Vaccine Summit held August 16-18, 2011 in Cambridge, MA.
A 2012 survey of internal medicine residents at Massachusetts General Hospital (MGH) - one of the nation's leading teaching hospitals - found that more than half rated the training they had received in addiction and other substance use disorders as fair or poor.
The American Heart Association will today present Gladstone Institutes Senior Investigator and President Emeritus Robert Mahley, MD, PhD, with the 2011 AHA Distinguished Scientist Award, bestowing yet another honor on one of Gladstone's founding cardiovascular scientists.
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).
More than 100 million people in this country have pain that won't go away. Many of these chronic pain sufferers fail to get relief from pills, shots and even surgery, while others temporarily trade the pain for side effects such as drowsiness or digestive problems.
Generex Biotechnology Corporation announced today that the Company's wholly-owned subsidiary Antigen Express, Inc. presented an update of the ongoing Phase 2 trial with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in patients with breast cancer at Cambridge Healthtech Institute's Sixth Annual ImVacS: The Immunotherapeutics and Vaccine Summit held August 16-18, 2011 in Cambridge, MA.
A 2012 survey of internal medicine residents at Massachusetts General Hospital (MGH) - one of the nation's leading teaching hospitals - found that more than half rated the training they had received in addiction and other substance use disorders as fair or poor.
The American Heart Association will today present Gladstone Institutes Senior Investigator and President Emeritus Robert Mahley, MD, PhD, with the 2011 AHA Distinguished Scientist Award, bestowing yet another honor on one of Gladstone's founding cardiovascular scientists.
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 21.43 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 1.63 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 45.21 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.59 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.54 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.48 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 9.09 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 27.35 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 56.7 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.83 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |